43 results
DEFA14A
VERV
Verve Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
7:56am
Additional Materials
Soliciting Material under §240.14a-12
Verve Therapeutics, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s … with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
P.O. BOX 8016, CARY, NC
DEFA14A
VERV
Verve Therapeutics Inc
28 Apr 23
Additional proxy soliciting materials
7:49am
Additional Materials
Soliciting Material under §240.14a-12
Verve Therapeutics, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s … with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
P.O. BOX 8016, CARY, NC
DEFA14A
VERV
Verve Therapeutics Inc
29 Apr 22
Additional proxy soliciting materials
7:22am
Materials
Soliciting Material under §240.14a-12
Verve Therapeutics, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s … with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
P.O. BOX 8016, CARY, NC 27512
DRS
EX-10.11
VERV
Verve Therapeutics Inc
16 Apr 21
Draft registration statement
12:00am
ARTICLE 2 GOVERNANCE
Management
Joint Development Committee
ARTICLE 3 THE PROGRAM
Program Generally
FTEs
Program Records, Reports and Materials
Permitted … Verve wishes to disclose Acuitas Confidential Information or transfer Acuitas LNP Technology or Materials provided by Acuitas to Verve, any Third-Party
S-1
EX-10.10
r2h xap3ussf7va29cg1
28 May 21
IPO registration
4:04pm
DEF 14A
q89 hj0q2x
29 Apr 22
Definitive proxy
7:01am
DRS
EX-10.10
fhpzy0 dg1
16 Apr 21
Draft registration statement
12:00am
S-1
EX-10.9
6oe9gqi 9gaj86nyml9y
28 May 21
IPO registration
4:04pm
10-Q
bhqw bqzehd
12 Aug 21
Quarterly report
8:53am
D
2sihtvoo6qptb4l0
22 Jan 21
$94M in equity, sold $94M, 22 investors
3:58pm